Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labo EuromedisFRA:61R +4.51%60 Earnings Yield (Joel Greenblatt) % is 142.86% as of Dec. 2025, which is 2908% above its 10-year median of 4.75. GuruFocus rates FRA:61R with a GF Score™ of 60/100 and a GF Value™ of €4.47. The stock has 6 warning signs investors should review. Among 124 Medical Distribution companies, Labo Euromedis ranks better than 93.55% on this metric.
Labo Euromedis's Enterprise Value for the quarter that ended in Dec. 2025 was €0.34 Mil.
Labo Euromedis's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €0.90 Mil. Labo Euromedis's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 142.86%.
The historical rank and industry rank for Labo Euromedis's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:61R'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2138.14 Med: 4.75 Max: 2629.44
Current: 22.62
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Labo Euromedis was 2629.44%. The lowest was -2138.14%. And the median was 4.75%.
FRA:61R's Earnings Yield (Joel Greenblatt) % is ranked better than 93.55% of 124
companies
in the Medical Distribution industry
Industry Median: 6.41
vs FRA:61R: 22.62
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Labo Euromedis's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Labo Euromedis Earnings Yield (Joel Greenblatt) % Related Terms
Labo Euromedis Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Labo Euromedis's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Earnings Yield (Joel Greenblatt) % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Labo Euromediss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 142.86% mean?
Labo Euromedis (FRA:61R) has a Earnings Yield (Joel Greenblatt) % of 142.86% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Labo Euromedis and its competitors. This is 2908% above median its historical median of 4.75. According to the industry distribution chart, Labo Euromedis ranks #8 out of 124 companies in the Medical Distribution industry, placing it in the top 6.5%.
Is Labo Euromedis' Earnings Yield (Joel Greenblatt) % too high?
Labo Euromedis' current Earnings Yield (Joel Greenblatt) % of 142.86% is 2908% above median its 10-year median of 4.75. The Medical Distribution industry median Earnings Yield (Joel Greenblatt) % is 6.41. Labo Euromedis' value of 142.86% is 2128.7% above this industry median. Based on the distribution chart, Labo Euromedis ranks #8 out of 124 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Labo Euromedis has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Earnings Yield (Joel Greenblatt) % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #8 out of 124 companies for Earnings Yield (Joel Greenblatt) %. This places Labo Euromedis in the top 7% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 6.41. Labo Euromedis' value of 142.86% is 2128.7% above this benchmark. While the company's 10-year median is 4.75 vs. the industry median of 6.41, Labo Euromedis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Distribution company?
The median Earnings Yield (Joel Greenblatt) % among Medical Distribution companies is 6.41, based on 124 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current Earnings Yield (Joel Greenblatt) % of 142.86% is 2128.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median Earnings Yield (Joel Greenblatt) % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Earnings Yield (Joel Greenblatt) % is 142.86%, which is 2908% above median its own 10-year median of 4.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current Earnings Yield (Joel Greenblatt) % of 142.86%. The stock's GF Value™ is €4.47, compared to a current price of €5.10 — trading 14.1% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 142.86%, which is 2908% above median its 10-year median of 4.75 and 2128.7% above the Medical Distribution industry median of 6.41. Labo Euromedis' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current Earnings Yield (Joel Greenblatt) % is 142.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €5.10 is trading 14.1% above its estimated GF Value™ of €4.47.
Key valuation signals for FRA:61R:
Earnings Yield (Joel Greenblatt) %: 142.86% (2908% above median its 10-year median of 4.75)
GF Value™: €4.47 vs. price of €5.10 (14.1% above fair value)
Industry Position: 2128.7% above the Medical Distribution median (#8 of 124)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
60GF Score
Get the complete analysis for FRA:61R
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
